BioMarin Pharmaceutical Inc.
105 Digital Drive
About BioMarin Pharmaceutical Inc.
At BioMarin, we focus on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. BioMarin remains steadfast to its original mission—to bring new treatments to market that will make a big impact on small patient populations. These patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options, and are usually ignored.
BioMarin offers a friendly, fast-paced, collegial environment where success is measured by both the individual and collective efforts of hundreds of talented scientists, business professionals, technical specialists and experts in a variety of fields from sales and marketing, to finance, to manufacturing, to clinical and regulatory operations.
BioMarin is growing rapidly to support the development and global commercialization of breakthrough drugs to treat rare genetic diseases. The company’s product portfolio comprises seven approved products and multiple clinical and pre-clinical product candidates.
You can make it happen at BioMarin, where the unique combination of big-company success in a small-company environment provides unparalleled opportunity for individual contributions and growth.
What makes working here unique? At BioMarin, we feel the intense tie between the work we do and the life-changing results it delivers. Our focus on rare disease gives us the rare opportunity to truly impact lives.
591 articles with BioMarin Pharmaceutical Inc.
Company Ranks 1st Among Midsize Employers in 'Drugs & Biotechnology' Industry
April 17, 2019 is the 29th World Hemophilia Day, a designated day to create awareness of the disease. Hemophilia is one of a number of bleeding disorders. The blood of people with hemophilia does not clot normally as the result of insufficient clotting factor. As a result, they can bleed for a lo...
The San Francisco Business Times came out with a list of 64 major Bay Area employers and their median pay, which they then compared to their chief executives’ annual compensation.
4/5/2019In January 2019, the U.S. Food and Drug Administration (FDA) updated a 2015 draft guidance on rare diseases.
BioMarin to Host First Quarter 2019 Financial Results Conference Call and Webcast on Thursday, April 25 at 4:30pm ET
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, April 25, at 4:30 p.m. ET to discuss first quarter 2019 financial results and provide a general business update.
BioMarin to Participate in Cowen and Company 39th Annual Health Care Conference on March 12 in Boston
A replay will be archived on the site for at least one week following each event.
BioMarin Receives Positive CHMP Opinion in Europe for Palynziq® (pegvaliase Injection) for Treatment of Patients with Phenylketonuria (PKU) Aged 16 and Older
In Phase 3 Trial, Palynziq Substantially Reduced Blood Phenylalanine Levels, While Increasing Dietary Protein; Data Suggestive of Beneficial Effects on Inattention and Mood Symptoms
Behind the Seizure™ Program Expansion Helps Speed the Diagnosis of Genetic Epilepsy in Younger Children Experiencing Unprovoked Seizures
--Stoke Therapeutics and Xenon Pharmaceuticals Join Founders BioMarin and Invitae to Offer a No-Cost Epilepsy Gene Panel Testing Program for Children Up to 60 Months Who Have Had an Unprovoked Seizure-- [26-February-2019] SAN FRANCISCO , Feb. 26, 2019 /PRNewswire/ -- As Rare Disease Day focuses attention on the challenges of diagnosing rare, often genetic conditions,
Global Phase 3 Vosoritide Study in Children with Achondroplasia Enrollment Complete with Data Expected by Year-end 2019
BioMarin Announces Ongoing Study Demonstrates Durable Treatment Benefit from Brineura® (cerliponase alfa) for 3 Years
Reduced Rate of Decline Maintained in Children with CLN2 Disease, a Form of Batten Disease
Presentations to Highlight Results from Studies for the Treatment of Three Forms of MPS and CLN2 Disease, a Form of Batten Disease
BioMarin to Host Fourth Quarter and Full Year 2018 Financial Results Conference Call and Webcast on Thursday, February 21 at 4:30pm ET
BioMarin Pharmaceutical Inc. announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, February 21, at 4:30 p.m. ET to discuss fourth quarter and full year 2018 financial results and provide a general business update.
BioMarin Highlights Key Milestones for 2019 at 37th Annual J.P. Morgan Healthcare Conference in San Francisco
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a company focused on innovative therapies to treat rare diseases, provided highlights to the investment community on its key milestones for 2019 at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco.
EvaluatePharma and Vantage recently released their Vantage 2019 Preview which looks at the current year’s biopharma market and makes projections about the upcoming year.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will participate in the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 8:30 am PT, or 11:30 am ET, in San Francisco, California.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that management will participate in Citi's 13th Annual Biotech Conference on December 5 in New York City.
BioMarin Pharmaceutical Inc. today announced the promotion of Amy Wireman to Group Vice President, Human Resources.
Florida-based Catalyst Pharma won regulatory approval for its treatment of a rare autoimmune disorder called Lambert-Eaton myasthenic syndrome (LEMS). The U.S. Food and Drug Administration approval of the new oral drug, Firdapse (amifampridine), is the first ever approved for this disease.
'Hemophilia: The Musical' allows teens to share their experiences with the genetic disease.
SAN RAFAEL, Calif., /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced the debut of the Broadway-style 'Hemophilia: The Musical,' a first-of-its-kind theatrical production featuring 25 students affected by a bleeding disorder.